Advances in targeted drugs, refined surgical techniques, and personalized treatment strategies are improving survival and quality of life for people with colorectal cancer. While overall rates of the disease are declining, medical teams are focusing on delivering more effective, less invasive care tailored to individual patients.
A significant pharmaceutical advance is the accelerated FDA approval of a new drug combination for a specific genetic subtype of advanced colorectal cancer. The targeted therapy adagrasib (Krazati), when combined with the established drug cetuximab, represents the first approved treatment targeting tumors with a KRAS-G12C mutation. In a key clinical trial involving 94 patients, this combination successfully stopped or shrank tumors. This mutation is present in roughly 4% of colorectal cancer cases and can be identified through standard tumor-sequencing tests.
Parallel progress is being made in surgical and local treatment approaches, with a strong emphasis on preserving patients' quality of life. Robot-assisted surgery, a minimally invasive technique, is now used in close to half of colorectal cancer surgeries at leading centers, with over 700 such procedures performed in one institution last year. This method is associated with less postoperative pain, lower infection rates, and reduced risk of complications like hernias.
For rectal cancer specifically, the innovative "watch and wait" protocol is allowing many patients to avoid major surgery altogether. After treatment with radiation and chemotherapy, patients are closely monitored. Recent research confirms this approach offers an identical survival rate to traditional rectum-removing surgery while significantly enhancing quality of life. Furthermore, some patients who do require surgery may now be able to forgo radiation, thanks to clinical trial data showing chemotherapy alone before surgery can be equally effective for certain cases.
Immunotherapy Breakthrough for Localized Cancers
A groundbreaking development involves using immunotherapy alone to cure a subset of rectal cancer. For the approximately 5% of rectal cancer patients whose tumors are Mismatch Repair Deficient (MMRd), a regimen of immune checkpoint blockade drugs has produced remarkable results. In a clinical trial, 100% of the more than 40 participants saw their tumors disappear completely without needing any surgery, chemotherapy, or radiation. This approach, which has received FDA Breakthrough Therapy Designation, is now being adopted globally and is also showing promise for treating other solid tumors with the same genetic signature.
The future of colorectal cancer care is increasingly precise and patient-centered. With a new targeted therapy now available, refined surgical techniques becoming standard, and paradigm-shifting immunotherapy protocols on the horizon, the focus is firmly on achieving cures while minimizing the long-term impact of treatment. These collective advances offer renewed hope for improved outcomes across all stages of the disease.